Justin Michael Oldham, M.D., M.S.
Critical Care Medicine
- Assistant Professor
- Director, Interstitial Lung Disease Program
Dr. Oldham serves as director of the Interstitial Lung Disease program at the University of California-Davis. He oversees the UC-Davis ILD patient registry and supervises the conduct of ILD clinical trials.
Dr. Oldham's research interest lies in translating ILD genetics research into clinical application. He is particularly interested in pharmacogenetics research to identify genetic subgroups most likely to benefit from ILD therapies.
M.D., University of Colorado School of Medicine, Denver CO 2006
M.S., Biostatistics and Epidemiology, University of Chicago, Chicago IL 2015
B.A., University of Colorado, Boulder CO 2002
Internal Medicine, UC Davis Medical Center, Sacramento CA 2007-2009
Pulmonary and Critical Care, University of Chicago, Chicago IL 2011-2016
American Board of Internal Medicine,
American Board of Internal Medicine, Pulmonary and Critical Care Medicine,
American College of Chest Physicians
American Thoracic Society
Honors and Awards
Pulmonary Fibrosis Foundation Summit Poster Award, 2015
American Thoracic Society Clinical Problems Abstract Award, 2015
Janet Rowley Research Day Clinical Abstract Award, 2014
Medical Student Teaching Award, 2010
Select Recent Publications
Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V, Fischer A, Noth I, Vij R, Strek ME. Characterization of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal. 2016.
Adegunsoye A, Oldham JM, Demchuk C, Montner S, Chung JH, Vij R, Strek ME. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory Medicine. 2016.
Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I; IPFnet Investigators. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015 Dec 15;192(12):1475-82.
Oldham JM, Kumar D, Lee C, Patel SB, Takahashi-Manns S, Demchuk C, Strek ME, Noth I. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015 Sep;148(3):692-700.
Huang Y, Ma SF, Vij R, Oldham JM, Herazo-Maya J, Broderick SM, Strek ME, White SR, Hogarth DK, Sandbo NK, Lussier YA, Gibson KF, Kaminski N, Garcia JG, Noth I. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Nov 21;15:147.
Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015 Oct;148(4):1055-62.
Denner DR, Sangwan N, Becker JB, Hogarth DK, Oldham J, Castillo J, Sperling AI, Solway J, Naureckas ET, Gilbert JA, White SR. Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways. J Allergy Clin Immunol. 2015 Nov 25. pii: S0091-6749(15)01563-8.
Patterson KC, Huang F, Oldham JM, Bhardwaj N, Hogarth DK, Mokhlesi B. Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis. Chest. 2013 Jun;143(6):1562-8.
Zeki AA, Oldham J, Wilson M, Fortenko O, Goyal V, Last M, Last A, Patel A, Last JA, Kenyon NJ. Statin use and asthma control in patients with severe asthma. BMJ Open. 2013 Aug 13;3(8).
Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med. 2014 Jun;108(6):819-29. Epub 2014 Apr 4. Review.